Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02444234 · ClinicalTrials.gov registry record · Phase 4
Pharmacokinetics of Tedizolid Phosphate in Cystic Fibrosis
A Phase 4 study of Cystic Fibrosis, sponsored by University of Southern California.
- Completed
- Registry status
- Phase 4
- Development phase
- 11
- Enrollment target
- 1
- Study location
NCT02444234: Completed Phase 4 study of Cystic Fibrosis, sponsored by University of Southern California.
NCT02444234 is a Phase 4 study of Cystic Fibrosis that has completed, run by University of Southern California. The registered enrollment target is 11 participants, below the 179-participant average among 169 other Cystic Fibrosis trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02444234, a Phase 4 study of Cystic Fibrosis, has completed, sponsored by University of Southern California.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 11 participants
- Enrollment target
- 1
- Study location
Study Summary
The proposed study is designed to characterize the pharmacokinetics of intravenous and oral tedizolid in patients with Cystic Fibrosis.
Primary Outcome
Cmax was calculated using data collected at 0, 0.5, 1, 2, 3, 4, 8, 24, 48 hours post-dose
Conditions Studied
Interventions
- DRUG Tedizolid PO
- DRUG Tedizolid IV
Study Locations (1)
California
- University of Southern California - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2015-07 |
| Est. Completion | 2017-12-31 |
| Phase | Phase 4 |
What the finished NCT02444234 record still lists
NCT02444234 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 11 participants, a relatively small participant target, below the 179-participant average among 169 other Cystic Fibrosis trials with a reported enrollment target (94% lower).
The record links to 1 condition, with Cystic Fibrosis appearing as the primary indexed condition, and to 2 interventions - of which Tedizolid PO is the first listed.
NCT02444234 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT02444234 about?
NCT02444234 is a clinical study titled "Pharmacokinetics of Tedizolid Phosphate in Cystic Fibrosis". The proposed study is designed to characterize the pharmacokinetics of intravenous and oral tedizolid in patients with Cystic Fibrosis.
What is the current status of trial NCT02444234?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 11 participants. The study started on 2015-07. Estimated completion is 2017-12-31.
What conditions does trial NCT02444234 study?
This clinical trial studies the following conditions: Cystic Fibrosis.
What interventions are being tested in trial NCT02444234?
The interventions under investigation include: Tedizolid PO (DRUG), Tedizolid IV (DRUG).
Who is sponsoring clinical trial NCT02444234?
This trial is sponsored by University of Southern California, which has 617 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02444234 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cystic Fibrosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02444234's enrollment target sits among peer trials
11 156th of 169 higher than 12 of 169 other Cystic Fibrosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cystic Fibrosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Markers of Osteoporosis in Cystic Fibrosis
RECRUITING · Phase 4
-
BEGIN Novel ImagiNG Biomarkers
RECRUITING · Phase 4
-
Estrogen Supplementation and Bone Health in Women With CF
RECRUITING · Phase 4
-
Standardizing Treatments for Pulmonary Exacerbations - Aminoglycoside Study
RECRUITING · Phase 4
-
Hyperpolarized Imaging for New Treatments
ACTIVE NOT RECRUITING · Phase 4
-
Non-contrast Lung Perfusion Mapping Applied for New Insights in Cystic Fibrosis
ACTIVE NOT RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03114462 · 11 participants · Phase 1
Trial of Stereotactic HYpofractionateD RadioAblative (HYDRA) Treatment of Laryngeal Cancer
- NCT06039709 · 11 participants · Phase 1
Sonodynamic Therapy in Patients With Recurrent GBM
- NCT06425380 · 11 participants · NA
Pilot Open-Label Trial of Resistant Potato Starch in Patients With Cirrhosis and Overt Hepatic Encephalopathy
- NCT06472661 · 11 participants · Early Phase 1
FUSA With Intratumoral PolyICLC in Regionally Advanced Resectable Melanoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia